Posted On: 10/22/2014 10:38:04 PM
Post# of 30034
Next bullet in the chamber.....
Parkinson’s Disease
Current Status: The Parkinson’s disease application of the NuroPro® Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus is preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
Parkinson’s Disease
Current Status: The Parkinson’s disease application of the NuroPro® Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus is preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
(0)
(0)Scroll down for more posts ▼
